



Standing Order for Administration of Vaccine 2025-2026 COVID-19 Vaccine for Pharmacies

Purpose: To reduce morbidity and mortality from COVID-19, this Standing Order authorizes qualified pharmacists, pharmacy interns, and pharmacy technicians to administer the 2025-2026 COVID-19 vaccine to individuals **ages 5 years and older** based on the recommendations of the Commissioner of the Vermont Department of Health, as supported by evidence-based guidance from the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, and the Infectious Diseases Society of America.

Authority: This Standing Order is issued pursuant to 18 V.S.A. § 2, 18 V.S.A. § 126, and 26 V.S.A. ch. 23 to mitigate the significant public health risk posed by COVID-19, a public health hazard that has harmed thousands of Vermonters. The Standing Order is to mitigate the significant public health risk by allowing individuals and their health care providers to choose scientifically-approved, evidence-based vaccines.

Policy: This Standing Order is a prescription for the 2025-2026 COVID-19 vaccine for individuals **ages 5 years and older**, to be fulfilled only at pharmacies located in the State of Vermont. After appropriate review by a pharmacist or pharmacy intern, the vaccine may be administered by a pharmacist, pharmacy intern, or pharmacy technician, consistent with their respective scopes of practice and the "Procedures" below.

Procedures: This order is effective until August 31, 2026, unless rescinded earlier. This Standing Order authorizes pharmacists, pharmacy interns, and pharmacy technicians to administer the 2025-2026 version of the COMIRNATY, MNEXSPIKE, SPIKEVAX, and NUVAXOVID COVID-19 vaccines to all persons **aged 5 years and older**, including pregnant individuals, consistent with recommendations issued by the Commissioner of the Vermont Department of Health and the terms and conditions of this Standing Order. The Vermont Immunization Registry should be used to assess vaccination status of each person prior to preparation and administration of vaccine.

1. Assess the Need for Vaccination Against COVID-19

This Standing Order authorizes vaccination with an age-appropriate 2025-2026 COVID-19 vaccine consistent with recommendations issued by the Commissioner of the Health Department and this Standing Order.

2. Provide Vaccine Information Statements

Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language if one is available and desired; these can be found at www.immunize.org/vis.

3. Screen for Contraindications and Precautions

- **Contraindications:**

- A severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine.

- **Precautions:**

- History of:

- A diagnosed non-severe allergy to a component of COVID-19 vaccine.
 - Non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.
 - Moderate to severe acute illness, with or without fever.
 - Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A).
 - Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.

Refer persons with medical questions, with potential contraindications or with health conditions that may indicate need for vaccination not covered by this order to a primary care provider for assessment and vaccination. <https://www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html>.

4. Prepare to Administer Vaccine

For vaccine that is to be administered intramuscularly, choose the needle gauge, needle length, and injection site according to the following chart: <https://www.immunize.org/wp-content/uploads/catg.d/p3085.pdf>

Intramuscular (IM) injection		
Use a 22–25 gauge needle. Choose the injection site and needle length that is appropriate to the person's age and body mass.		
AGE	NEEDLE LENGTH	INJECTION SITE
Children (3 through 10 yrs)	$\frac{5}{8}$ – 1"	Deltoid muscle of arm ⁶
	1 – 1¼"	Anterolateral thigh muscle
Adolescents and teens (11 through 18 yrs)	$\frac{5}{8}$ – 1"	Deltoid muscle of arm ⁶
	1 – 1½"	Anterolateral thigh muscle
Biological sex and weight of patient 19 yrs or older	NEEDLE LENGTH	INJECTION SITE
Female or male <130 lbs	$\frac{5}{8}$ – 1"	Deltoid muscle of arm
Female or male 130–152 lbs	1"	Deltoid muscle of arm
Female 153–200 lbs Male 153–260 lbs	1 – 1½"	Deltoid muscle of arm
Female more than 200 lbs Male more than 260 lbs	1½"	Deltoid muscle of arm
Female or male, any weight	1 ⁵ – 1½"	Anterolateral thigh muscle

5. Administer any recommended, age-appropriate COVID-19 vaccine using the vaccine product and dosing chart below, and according to the individual's immunocompromised status following the tables included in Appendix A and Appendix B.

Age	COVID-19 Vaccine Product	Dosage
5 years through 11 years	Pfizer-BioNTech (Comirnaty)	0.3 mL/10 µg
	Moderna (Spikevax)	0.25 mL/25 µg
12 years and older	Pfizer-BioNTech (Comirnaty)	0.3 mL/30 µg
	Moderna (Spikevax)	0.5 mL/50 µg
	Moderna (mNEXSPIKE)	0.2 mL/10 µg
	Novavax (Nuvaxvoid)	0.5 mL/5 µg rS and 50 µg of Matrix-M adjuvant

6. Document the following details in the vaccine administration record and the Vermont Immunization Registry (complete information in any personal record carried by the patient):

- Date administered
- Manufacturer
- Site of vaccination
- Route of vaccination
- Name and title of vaccinator
- VIS publication date and date given to patient/representative
- Clinic location
- VFC eligibility
- Race, ethnicity

7. Prepare for management of a medical emergency by having the following:

Be prepared for management of a medical emergency related to the administration of vaccine by having a written emergency medical protocol available, as well as equipment and medications. Maintain and follow policies in accordance with General Best Practices for Immunization (<https://www.cdc.gov/vaccines/hcp/imz-best-practices/preventing-managing-adverse-reactions.html>) and see Considerations for people with a history of allergies or allergic reactions (https://www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html#cdc_vaccine_special_topics_research-considerations-for-people-with-a-history-of-allergies-or-allergic-reactions) for more information.

8. Report any adverse event to the Vaccine Adverse Event Reporting System (VAERS)

Report all adverse events following the administration of COVID-19 vaccines to the federal Vaccine Adverse Event Reporting System (VAERS) (<https://vaers.hhs.gov/reportevent.html>).

DocuSigned by:

 B4F263BC82A544A...
 Julie Arel, Interim Commissioner
 Vermont Department of Health

9/17/2025

Effective Date

Signed by:



9E3DC1EF2394467...

Michael E. Rapaport, MD

Vermont Department of Health

9/17/2025

Effective Date

Information for Pharmacists:

Michael E. Rapaport, MD

NPI: 1134146962

Vermont License: 042.0009415

Vermont Department of Health, 280 State Drive, Waterbury, VT 05671-8300

APPENDIX A: ROUTINE 2025–2026 COVID-19 VACCINATION SCHEDULE FOR PEOPLE WHO ARE NOT MODERATELY OR SEVERELY IMMUNOCOMPROMISED

**TABLE 1A: AGES 5 YEARS THROUGH 11 YEARS
NOT MODERATELY OR SEVERELY IMMUNOCOMPROMISED**

COVID-19 vaccination history before 2025–2026 COVID-19 vaccine [†]	Number of 2025–2026 COVID-19 doses indicated	Recommended 2025–2026 COVID-19 vaccine [‡] and interval between doses
Unvaccinated: Receive one dose of 2025–2026 COVID-19 vaccine		
Unvaccinated	1	2025–2026 1 Dose (Moderna or Pfizer-BioNTech)
Previously vaccinated before 2025–2026 COVID-19 vaccine: • Receive 1 dose of 2025–2026 COVID-19 vaccine		
1 or more doses mRNA (Moderna or Pfizer-BioNTech) vaccine	1	2025–2026 1 Dose (Moderna or Pfizer-BioNTech): At least 8 weeks after last dose

[†]COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2025–2026 COVID-19 vaccines and includes original, bivalent, 2023–2024, and 2024–2025 COVID-19 vaccines.

[‡]Dosage for Moderna: 0.25 mL/25 µg; dosage for Pfizer-BioNTech: 0.3 mL/10 µg.

**TABLE 1B: AGES 12 THROUGH 64 YEARS, INCLUDING PEOPLE WHO ARE PREGNANT
NOT MODERATELY OR SEVERELY IMMUNOCOMPROMISED**

COVID-19 vaccination history before 2025–2026 COVID-19 vaccine ^{*†}	Number of 2025–2026 COVID-19 doses indicated	Recommended 2025–2026 COVID-19 vaccine [‡] and interval between doses
Unvaccinated: Initiate vaccination with 2025–2026 COVID-19 vaccine		
Unvaccinated	1	2025–2026 1 Dose of Moderna or Pfizer-BioNTech
	OR	
	2	2025 – 2026 2 doses Novavax at 0,3-8 weeks
Previously vaccinated before 2025–2026 COVID-19 vaccine: Receive 1 dose of 2025–2026 COVID-19 vaccine		
1 or more doses mRNA (Moderna or Pfizer-BioNTech) vaccine	1	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose
1 dose Novavax	1	2025–2026 Dose 1 (Novavax): 3–8 weeks after last dose ^{§¶}
2 or more doses Novavax	1	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose

^{*}COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2025–2026 COVID-19 vaccines and includes original, bivalent, 2023–2024, and 2024–2025 COVID-19 vaccines.

[†]People ages 18–64 years who received 1 or more doses of Janssen COVID-19 Vaccine should receive 1 dose of any 2025–2026 COVID vaccine.

[‡]Dosage for Moderna: 0.5 mL/50 µg; dosage for Novavax: 0.5 mL/5 µg rS protein and 50 µg Matrix-M adjuvant; dosage for Pfizer-BioNTech: 0.3 mL/30 µg.

[§]An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.

[¶]If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2025–2026 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.

TABLE 1C: 65 YEARS AND OLDER
NOT MODERATELY OR SEVERELY IMMUNOCOMPROMISED

COVID-19 vaccination history before 2025–2026 COVID-19 vaccine*†	Number of 2025–2026 COVID-19 doses indicated	Recommended 2025–2026 COVID-19 vaccine‡ and interval between doses
Unvaccinated: Initiate vaccination with 2025–2026 COVID-19 vaccine		
Unvaccinated	2	2025–2026 Dose 1 (Moderna or Pfizer-BioNTech) 2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 1
	3	OR 2025–2026 Dose 1 (Novavax): Day 0 2025–2026 Dose 2 (Novavax): 3–8 weeks after Dose 1 [§] 2025–2026 Dose 3 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 2
Previously vaccinated before 2025–2026 COVID-19 vaccine: Receive 1 dose of 2025–2026 COVID-19 vaccine		
1 or more doses mRNA (Moderna or Pfizer-BioNTech) vaccine	2	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose 2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1
1 dose Novavax	2	2025–2026 Dose 1 (Novavax): 3–8 weeks after last dose ^{§¶} 2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1
2 or more doses Novavax	2	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose 2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1

*COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2025–2026 COVID-19 vaccines and includes original, bivalent, 2023–2024 and 2024–2025 COVID-19 vaccines.

†People ages 65 years and older who received 1 or more doses of Janssen COVID-19 Vaccine should receive a first dose of any 2025–2026 COVID-19 vaccine followed by a second dose of any 2025–2026 COVID-19 vaccine 6 months (minimum interval 2 months) after the first dose.

‡Dosage for Moderna: 0.5 mL/50 µg; dosage for Novavax: 0.5 mL/5 µg rS protein and 50 µg Matrix-M adjuvant; dosage for Pfizer-BioNTech: 0.3 mL/30 µg.

§An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.

¶If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.

**APPENDIX B: 2025–2026 COVID-19 VACCINATION SCHEDULE
FOR PEOPLE WHO ARE MODERATELY OR SEVERELY IMMUNOCOMPROMISED**

**TABLE 2A: AGES 5 YEARS THROUGH 11 YEARS*
MODERATELY OR SEVERELY IMMUNOCOMPROMISED**

COVID-19 vaccination history before 2025–2026 COVID-19 vaccine [†]	Number of 2025–2026 COVID-19 doses indicated	Recommended 2025–2026 COVID-19 vaccine [‡] and interval between doses
Unvaccinated:		
<ul style="list-style-type: none"> Receive an initial 3-dose series with 2025–2026 vaccine Receive 1 dose of 2025–2026 vaccine 6 months (minimum interval 2 months) after completing initial series May receive additional doses of 2025–2026 vaccine under shared clinical decision-making[§] 		
Unvaccinated	4	2025–2026 Dose 1 (Moderna): Day 0 2025–2026 Dose 2 (Moderna): 4 weeks after Dose 1 2025–2026 Dose 3 (Moderna): At least 4 weeks after Dose 2 2025–2026 Dose 4 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 3 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025– 2026 Moderna dose [§]
	OR	
	4	2025–2026 Dose 1 (Pfizer-BioNTech): Day 0 2025–2026 Dose 2 (Pfizer-BioNTech): 3 weeks after Dose 1 2025–2026 Dose 3 (Pfizer-BioNTech): At least 4 weeks after Dose 2 2025–2026 Dose 4 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 3 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025–2026 mRNA dose [§]
Initiated but did not complete the initial series before 2025–2026 vaccine:		
<ul style="list-style-type: none"> Complete the 3-dose series with 2025–2026 vaccine Receive 1 dose of 2025–2026 vaccine 6 months (minimum interval 2 months) after completing initial series May receive additional doses of 2025–2026 vaccine under shared clinical decision-making[§] 		
1 dose Moderna	3	2025–2026 Dose 1 (Moderna): 4 weeks after last dose 2025–2026 Dose 2 (Moderna): At least 4 weeks after 2025–2026 Dose 1 2025–2026 Dose 3 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 2 Additional doses (Moderna or Pfizer-BioNTech): May be administered

		under shared clinical-decision making at least 2 months after last 2025– 2026 mRNA dose ^s
2 doses Moderna	2	2025–2026 Dose 1 (Moderna): At least 4 weeks after last dose 2025–2026 Dose 2 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025–2026 mRNA dose ^s
1 dose Pfizer-BioNTech	3	2025–2026 Dose 1 (Pfizer-BioNTech): 3 weeks after last dose 2025–2026 Dose 2 (Pfizer-BioNTech): At least 4 weeks after 2025–2026 Dose 1 2025–2026 Dose 3 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 2 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025–2026 mRNA dose ^s
2 doses Pfizer-BioNTech	2	2025–2026 Dose 1 (Pfizer-BioNTech): At least 4 weeks after last dose 2025–2026 Dose 2 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 2 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025–2026 mRNA dose ^s
Completed the 3-dose initial series before 2025–2026 vaccine:		
<ul style="list-style-type: none"> ● Receive 2 doses of 2025–2026 vaccine spaced 6 months (minimum interval 2 months) apart ● May receive additional doses of 2025–2026 vaccine under shared clinical decision-making^s 		
3 or more doses Moderna or Pfizer	2	2025–2026 Dose 1 (Moderna or Pfizer-BioNTech): At least 8 weeks after last dose 2025–2026 Dose 2 (Moderna or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last 2025–2026 mRNA dose ^s

*Children who transition from age 4 years to age 5 years during the initial vaccination series should complete the 3-dose series using the dosage for children ages 5–11 years for all doses received on or after turning age 5 years:

- Moderna series: 2025–2026 Moderna, 0.25 mL/25 µg; there is no dosage change
- Pfizer-BioNTech series: 2025–2026 Pfizer-BioNTech, 0.3 mL/10 µg

†COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2025–2026 COVID-19 vaccines and includes original, bivalent, 2023–2024, and 2024–2025 COVID-19 vaccines.

‡Dosage for Moderna: 0.25 mL/25 µg; dosage for Pfizer-BioNTech: 0.3 mL/10 µg.

§Additional doses may be administered, informed by the clinical judgment of a healthcare provider and personal preference and circumstances.

¶This COVID-19 vaccine history refers to previous receipt of 3 doses of mRNA vaccine from the same manufacturer (i.e., Moderna or Pfizer- BioNTech) for initial vaccination followed by 1 or more additional doses of any mRNA vaccine.

TABLE 2B: AGES 12 YEARS AND OLDER*
MODERATELY OR SEVERELY IMMUNOCOMPROMISED

COVID-19 vaccination history before 2025–2026 COVID-19 vaccine ^{†‡}	Number of 2025–2026 COVID-19 doses indicated	Recommended 2025–2026 COVID-19 vaccine [§] and interval between doses
Unvaccinated: <ul style="list-style-type: none"> Receive an initial series with 2025–2026 vaccine Receive 1 dose of 2025–2026 vaccine 6 months (minimum interval 2 months) after completing initial series May receive additional doses of 2025–2026 vaccine under shared clinical decision-making 		
Unvaccinated	4	2025–2026 Dose 1 (Moderna): Day 0 2025–2026 Dose 2 (Moderna): 4 weeks after Dose 1 2025–2026 Dose 3 (Moderna): At least 4 weeks after Dose 2 2025–2026 Dose 4 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 3 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine
	OR	
	3	2025–2026 Dose 1 (Novavax): Day 0 2025–2026 Dose 2 (Novavax): 3 weeks after Dose 1 2025–2026 Dose 3 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 2 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine
	4	2025–2026 Dose 1 (Pfizer-BioNTech): Day 0 2025–2026 Dose 2 (Pfizer-BioNTech): 3 weeks after Dose 1 2025–2026 Dose 3 (Pfizer-BioNTech): At least 4 weeks after Dose 2 2025–2026 Dose 4 (Moderna, Novavax or Pfizer-BioNTech): 6 months (minimum interval 2 months) after Dose 3 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine
Initiated but did not complete the initial series before 2025–2026 vaccine: <ul style="list-style-type: none"> Complete the initial series with 2025–2026 vaccine Receive 1 dose of 2025–2026 vaccine 6 months (minimum interval 2 months) after completing initial series May receive additional doses of 2025–2026 vaccine under shared clinical decision-making 		

1 dose Moderna	3	<p>2025–2026 Dose 1 (Moderna): 4 weeks after last dose</p> <p>2025–2026 Dose 2 (Moderna): At least 4 weeks after 2025–2026 Dose 1</p> <p>2025–2026 Dose 3 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 2 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine</p>
2 doses Moderna	2	<p>2025–2026 Dose 1 (Moderna): At least 4 weeks after last dose</p> <p>2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1</p> <p>Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine</p>
1 dose Pfizer-BioNTech	3	<p>2025–2026 Dose 1 (Pfizer-BioNTech): 3 weeks after last dose</p> <p>2025–2026 Dose 2 (Pfizer-BioNTech): At least 4 weeks after 2025–2026 Dose 1</p> <p>2025–2026 Dose 3 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 2 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine</p>
2 doses Pfizer-BioNTech	2	<p>2025–2026 Dose 1 (Pfizer-BioNTech): At least 4 weeks after last dose</p> <p>2025–2026 Dose 2 (Moderna, Novavax, or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna, Novavax, or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine</p>
1 dose Novavax	2	<p>2025–2026 Dose 1 (Novavax): At least 3 weeks after last dose</p> <p>2025–2026 Dose 2 (Moderna, Novavax or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna, Novavax or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine</p>

Completed the initial series before 2025–2026 vaccine:		
<ul style="list-style-type: none"> • Receive 2 doses of 2025–2026 vaccine spaced 6 months (minimum interval 2 months) apart • May receive additional doses of 2025–2026 vaccine under shared clinical decision-making 		
3 or more doses Moderna or Pfizer [#]	2	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose 2025–2026 Dose 2 (Moderna, Novavax or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna, Novavax or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine
2 or more doses Novavax [#]	2	2025–2026 Dose 1 (Moderna, Novavax or Pfizer-BioNTech): At least 8 weeks after last dose 2025–2026 Dose 2 (Moderna, Novavax or Pfizer-BioNTech): 6 months (minimum interval 2 months) after 2025–2026 Dose 1 Additional doses (Moderna, Novavax or Pfizer-BioNTech): May be administered under shared clinical decision-making at least 2 months after last dose of any 2025–2026 vaccine

*Children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received on or after turning age 12 years:

Moderna series: 2025–2026 Moderna, 0.5 mL/50 µg. OR: Pfizer-BioNTech series: 2025–2026 Pfizer-BioNTech, 0.3 mL/30 µg.

[†]COVID-19 vaccination history refers to all doses of COVID-19 vaccine from any manufacturer received before the availability of the 2025–2026 COVID-19 vaccines and includes original, bivalent, 2023–2024, and 2024–2025 COVID-19 vaccines.

[‡]People ages 18 years and older who received 1 or more doses of Janssen COVID-19 Vaccine should receive 1 dose of any 2025–2026 COVID-19 vaccine followed by a second dose of any 2025–2026 COVID-19 vaccine 6 months (minimum interval 2 months) after the first dose. Additional doses of any 2025–2026 COVID-19 vaccine may be administered under shared clinical decision-making at least 2 months after the last dose of any 2025–2026 vaccine.

[§]Dosage for Moderna: 0.5 mL/50 µg; dosage for Novavax: 0.5 mL/5 µg rS protein and 50 µg Matrix-M adjuvant; dosage for Pfizer-BioNTech: 0.3 mL/30 µg.

[¶]Additional doses may be administered, informed by the clinical judgment of a healthcare provider and personal preference and circumstances. [#]This COVID-19 vaccine history refers to previous receipt of 3 doses of mRNA vaccine from the same manufacturer (i.e., Moderna or Pfizer-BioNTech) for initial vaccination or 2 doses of Novavax for initial vaccination followed by 1 or more additional doses of any COVID-19 vaccine.